Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14279/1064
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kanellakopoulou, Kyriaki | - |
dc.contributor.author | Galani, Irene | - |
dc.contributor.author | Giamarellou, Helen J. | - |
dc.contributor.author | Giamarellos-Bourboulis, Evangelos J. | - |
dc.contributor.author | Sarafis, Pavlos | - |
dc.date.accessioned | 2015-04-30T10:27:51Z | - |
dc.date.accessioned | 2015-12-02T08:44:27Z | - |
dc.date.available | 2015-04-30T10:27:51Z | - |
dc.date.available | 2015-12-02T08:44:27Z | - |
dc.date.issued | 2008-07 | - |
dc.identifier.citation | International Journal of Antimicrobial Agents, 2008, vol. 32, iss. 1, pp. 33–39 | en_US |
dc.identifier.issn | 18727913 | - |
dc.identifier.uri | https://hdl.handle.net/20.500.14279/1064 | - |
dc.description.abstract | In vitro combinations of β-lactams with fluoroquinolones against multidrug-resistant (MDR) Pseudomonas aeruginosa were tested. From a total of 200 isolates, 24 genetically distinct isolates defined by pulsed-field gel electrophoresis (PFGE) were selected. The isolates were exposed over time to imipenem, meropenem and ceftazidime as well as to their combinations with ciprofloxacin and moxifloxacin. All isolates were resistant to all agents tested at concentrations equal to their average serum level. Synergy of any of the tested combinations was found in 10 isolates (41.7%). This was shown after 4 h and 6 h of exposure accompanied by re-growth after 24 h. Not all the tested combinations were active against the same isolates. The combinations of imipenem + ciprofloxacin, ceftazidime + ciprofloxacin and imipenem + moxifloxacin were the most active. When time–kill assays were repeated for the latter isolates at antimicrobial concentrations equal to their maximum serum levels, synergy was prolonged to 24 h. The present findings should be interpreted with caution for the management of infections by MDR P. aeruginosa. They underscore the potential interest of reporting synergism between β-lactams and fluoroquinolones in the nosocomial setting when a MDR isolate emerges. | en_US |
dc.format | en_US | |
dc.language.iso | en | en_US |
dc.relation.ispartof | International Journal of Antimicrobial Agents | en_US |
dc.rights | © Elsevier | en_US |
dc.subject | Ceftazidime | en_US |
dc.subject | Carbapenems | en_US |
dc.subject | Ciprofloxacin | en_US |
dc.subject | Moxifloxacin | en_US |
dc.subject | Pseudomonas aeruginosa | en_US |
dc.subject | Resistance | en_US |
dc.title | In vitro synergism of β-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa | en_US |
dc.type | Article | en_US |
dc.collaboration | National and Kapodistrian University of Athens | en_US |
dc.subject.category | Basic Medicine | en_US |
dc.journals | Subscription | en_US |
dc.review | Peer Reviewed | en |
dc.country | Greece | en_US |
dc.subject.field | Medical and Health Sciences | en_US |
dc.publication | Peer Reviewed | en_US |
dc.identifier.doi | 10.1016/j.ijantimicag.2008.02.019 | en_US |
dc.dept.handle | 123456789/54 | en |
dc.relation.issue | 1 | en_US |
dc.relation.volume | 32 | en_US |
cut.common.academicyear | 2008-2009 | en_US |
dc.identifier.spage | 33 | en_US |
dc.identifier.epage | 39 | en_US |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | article | - |
item.languageiso639-1 | en | - |
crisitem.journal.journalissn | 1872-7913 | - |
crisitem.journal.publisher | Elsevier | - |
crisitem.author.dept | Department of Nursing | - |
crisitem.author.faculty | Faculty of Health Sciences | - |
crisitem.author.orcid | 0000-0001-9967-5152 | - |
crisitem.author.parentorg | Faculty of Health Sciences | - |
Appears in Collections: | Άρθρα/Articles |
CORE Recommender
SCOPUSTM
Citations
16
checked on Nov 9, 2023
WEB OF SCIENCETM
Citations
20
12
Last Week
0
0
Last month
0
0
checked on Oct 29, 2023
Page view(s) 10
501
Last Week
3
3
Last month
12
12
checked on May 11, 2024
Google ScholarTM
Check
Altmetric
Items in KTISIS are protected by copyright, with all rights reserved, unless otherwise indicated.